The role of the TSC-22 (-396) A/G variant in the development of diabetic nephropathy

Diabetes Res Clin Pract. 2003 Jun;60(3):191-7. doi: 10.1016/s0168-8227(03)00038-x.

Abstract

TSC-22 is a leucine zipper transcriptional factor and expression of the TSC-22 gene is highly induced by TGF-beta treatment. We estimated the frequency of the -396 A/G polymorphism of the TSC-22 gene with an Alu I-Restriction fragment length polymorphism (RFLP) method in 498 Japanese subjects with type 2 diabetes mellitus. We also determined the promoter activity. The diabetic patients with the AA genotype had a significantly higher incidence of the diabetic nephropathy (vs. the AG genotype, P<0.05, odds ratio: 1.95; 95% confidence intervals 1.14-3.33). There was no significant difference in the promoter activity between the fragments with -396A and -396G. These findings suggest that the TSC-22 gene (-396) A allele is associated with an increasing risk of the diabetic nephropathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Diabetes Mellitus, Type 2 / genetics*
  • Diabetic Nephropathies / genetics*
  • Female
  • Genotype
  • Humans
  • Logistic Models
  • Luciferases / metabolism
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Polymorphism, Restriction Fragment Length
  • Promoter Regions, Genetic
  • Repressor Proteins*
  • Transcription Factors / genetics*
  • Transforming Growth Factor beta

Substances

  • Repressor Proteins
  • TSC22D1 protein, human
  • Transcription Factors
  • Transforming Growth Factor beta
  • Luciferases